At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Pracinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
In Brief
A Phase 2 clinical trial evaluating Pracinostat and Azacitidine for Acute Myeloid Leukemia. Completed, enrolled 50 participants across 17 sites.
Detailed Summary
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartDec 2013
Primary CompletionNov 2016
TodayJul 2026
First PostedJul 31, 2013
Enrollment StartDec 24, 2013
Primary CompletionNov 8, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.9 years ago
Interventions
Pracinostatdrug
Elderly newly diagnosed patients will all receive pracinostat
Azacitidinedrug
Elderly newly diagnosed patients will all receive azacitadine